The AAPS Journal

, Volume 13, Issue 2, pp 299–308 | Cite as

Evaluation of Physical and Chemical Changes in Pharmaceuticals Flown on Space Missions

  • Brian Du
  • Vernie R. Daniels
  • Zalman Vaksman
  • Jason L. Boyd
  • Camille Crady
  • Lakshmi PutchaEmail author
Research Article


Efficacy and safety of medications used for the treatment of astronauts in space may be compromised by altered stability in space. We compared physical and chemical changes with time in 35 formulations contained in identical pharmaceutical kits stowed on the International Space Station (ISS) and on Earth. Active pharmaceutical content (API) was determined by ultra- and high-performance liquid chromatography after returning to Earth. After stowage for 28 months in space, six medications aboard the ISS and two of matching ground controls exhibited changes in physical variables; nine medications from the ISS and 17 from the ground met the United States Pharmacopeia (USP) acceptance criteria for API content after 28 months of storage. A higher percentage of medications from each flight kit had lower API content than the respective ground controls. The number of medications failing API requirement increased as a function of time in space, independent of expiration date. The rate of degradation was faster in space than on the ground for many of the medications, and most solid dosage forms met USP standard for dissolution after storage in space. Cumulative radiation dose was higher and increased with time in space, whereas temperature and humidity remained similar to those on the ground. Exposure to the chronic low dose of ionizing radiation aboard the spacecraft as well as repackaging of solid dosage forms in flight-specific dispensers may adversely affect stability of pharmaceuticals. Characterization of degradation profiles of unstable formulations and identification of chemical attributes of stability in space analog environments on Earth will facilitate development of space-hardy medications.


chromatography dissolution pharmaceutical stability potency space radiation 



This research was funded by an NRA research grant from the National Aeronautics and Space Administration (NASA).

The authors acknowledge and appreciate the technical support provided by team members of the NASA Non-exercise Physiological Countermeasures Project and the International Space Station Medical Project. We thank Dr. Ramona Garza, a scientist from Universities Space Research Association, for providing reports of radiation dosimetry data and for her guidance on space radiation results for this study.

Supplementary material

12248_2011_9270_MOESM1_ESM.doc (51 kb)
Table S I (DOC 51 kb)
12248_2011_9270_MOESM2_ESM.doc (63 kb)
Table S II (DOC 63 kb)
12248_2011_9270_MOESM3_ESM.doc (66 kb)
Table S III A (DOC 66 kb)
12248_2011_9270_MOESM4_ESM.doc (132 kb)
Table S III B (DOC 131 kb)


  1. 1.
  2. 2.
    Lucas T, Bishara R, Seevers RH. A stability program for the distribution of drug products. Pharm Technol. 2004;2:68–73.Google Scholar
  3. 3.
    Chen XQ, Antman MD, Gesenberg C, Gudmundsson OS. Discovery pharmaceutics—challenges and opportunities. AAPS J. 2006;8(2):E402–8.PubMedGoogle Scholar
  4. 4.
    Carstensen JT. Stability of solids and solid dosage forms. J Pharm Sci. 1974;63(1):1–14.PubMedCrossRefGoogle Scholar
  5. 5.
    Putcha L, Berens KL, Marshburn TH, Ortega HJ, Billica RD. Pharmaceutical use by U.S. astronauts on space shuttle missions. Aviat Space Environ Med. 1999;70(7):705–8.PubMedGoogle Scholar
  6. 6.
    Tietze KJ, Putcha L. Factors affecting drug bioavailability in space. J Clin Pharmacol. 1994;34(6):671–6.PubMedGoogle Scholar
  7. 7.
    Cosa G, Scaiano JC. Laser techniques in the study of drug photochemistry. Photochem Photobiol. 2004;80(2):159–74.PubMedCrossRefGoogle Scholar
  8. 8.
    Langner MD, Maibach HI. Many common drugs in dermatology are light, temperature, or moisture-sensitive. Skin Therapy Lett. 2009;14(1):3–5.PubMedGoogle Scholar
  9. 9.
    Lyon RC, Taylor JS, Porter DA, Prasanna HR, Hussain AS. Stability profiles of drug products extended beyond labeled expiration dates. J Pharm Sci. 2006;95(7):1549–60.PubMedCrossRefGoogle Scholar
  10. 10.
    Matsumoto M, Kojima K, Nagano H, Matsubara S, Yokota T. Photostability and biological activity of fluoroquinolones substituted at the 8 position after UV irradiation. Antimicrob Agents Chemother. 1992;36(8):1715–9.PubMedGoogle Scholar
  11. 11.
    Phillips G, Johnson BE, Ferguson J. The loss of antibiotic activity of ciprofloxacin by photodegradation. J Antimicrob Chemother. 1990;26(6):783–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Okeke CC, Srinivasan VS. Expiration and beyond-use dates. Am J Health Syst Pharm. 1998;55(5):433–4.PubMedGoogle Scholar
  13. 13.
    Okeke CC, Bailey L, Medwick T, Grady LT. Revised USP standards for product dating, packaging, and temperature monitoring. Am J Health Syst Pharm. 2000;57(15):1441–5.PubMedGoogle Scholar
  14. 14.
    Parks OW. Screening tests for sulfa drugs and/or dinitrobenzamide coccidiostats and their monoamino metabolites in chicken livers. J Assoc Off Anal Chem. 1985;68(1):20–3.PubMedGoogle Scholar
  15. 15.
    Allinson JG, Dansereau RJ, Sakr A. The effects of packaging on the stability of a moisture sensitive compound. Int J Pharm. 2001;221(1–2):49–56.PubMedCrossRefGoogle Scholar
  16. 16.
    Van Weeren R, Sashidharan A. Sensitivity profiling of solid oral doses. Pharm Process. Apr 22 2008; 1–5.Google Scholar
  17. 17.
    Zwart SR, Kloeris VL, Perchonok MH, Braby L, Smith SM. Assessment of nutrient stability in foods from the space food system after long-duration space flight on the ISS. Food Sci. 2009;74(7):209–17.CrossRefGoogle Scholar
  18. 18.
    Abramowicz M. Drugs past their expiration date. Med Lett. 2002;44(W1142B):93–4.Google Scholar
  19. 19.
    Patel H, Stalcup A, Dansereau R, Sakr A. The effect of excipients on the stability of levothyroxine sodium pentahydrate tablets. Int J Pharm. 2003;264(1–2):35–43.PubMedCrossRefGoogle Scholar
  20. 20.
    Bosakova Z, Klouckova I, Tesarova E. Study of the stability of promethazine enantiomers by liquid chromatography using a vancomycin-bonded chiral stationary phase. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;770(1–2):63–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Moore TD, Horton R, Utrup LJ, Miller LA, Poupard JA. Stability of amoxicillin-clavulanate in BACTEC medium determined by high-performance liquid chromatography and bioassay. J Clin Microbiol. 1996;34(5):1321–2.PubMedGoogle Scholar
  22. 22.
    Vahdat L, Sunderland VB. Kinetics of amoxicillin and clavulanate degradation alone and in combination in aqueous solution under frozen conditions. Int J Pharm. 2007;342(1–2):95–104.PubMedCrossRefGoogle Scholar
  23. 23.
    Scholtissek C, Webster RG. Long-term stability of the anti-influenza A compounds—amantadine and rimantadine. Antiviral Res. 1998;38(3):213–5.PubMedCrossRefGoogle Scholar
  24. 24.
    Wu Y, Fassihi R. Stability of metronidazole, tetracycline HCl and famotidine alone and in combination. Int J Pharm. 2005;290(1–2):1–13.PubMedGoogle Scholar
  25. 25.
    Barbarina N, Tilquin B, de Hoffmann E. Radiosterilization of cefotaxime: investigation of potential degradation compounds by liquid chromatography-electrospray mass spectrometry. J Chromatogr A. 2001;929(1–2):51–61.PubMedCrossRefGoogle Scholar
  26. 26.
    Maggi L, Segale L, Ochoa ME, Buttafava A, Faucitano A, Conte U. Chemical and physical stability of hydroxypropylmethylcellulose matrices containing diltiazem hydrochloride after gamma irradiation. J Pharm Sci. 2003;92(1):131–41.PubMedCrossRefGoogle Scholar
  27. 27.
    Kane MP, Tsuji K. Radiolytic degradation scheme for 60Co-irradiated corticosteroids. J Pharm Sci. 1983;72(1):30–5.PubMedCrossRefGoogle Scholar
  28. 28.
    Ahrabi SF, Sande SA, Waaler T, Graffner C. Effects of thermal neutron irradiation on some potential excipients for colonic delivery systems. Drug Dev Ind Pharm. 1999;25(4):453–62.PubMedCrossRefGoogle Scholar
  29. 29.
    Benton ER, Benton EV. Space radiation dosimetry in low-Earth orbit and beyond. Nucl Instrum Methods Phys Res B. 2001;184(1–2):255–94.PubMedCrossRefGoogle Scholar
  30. 30.
    National Council on Radiation Protection and Measurements (NCRP). Guidance on radiation received in space activities: report No. 98. Bethesda: NCRP; 1989.Google Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2011

Authors and Affiliations

  • Brian Du
    • 1
  • Vernie R. Daniels
    • 1
  • Zalman Vaksman
    • 2
  • Jason L. Boyd
    • 3
  • Camille Crady
    • 1
  • Lakshmi Putcha
    • 4
    Email author
  1. 1.Wyle Integrated Science and Engineering GroupHoustonUSA
  2. 2.Texas Medical CenterUniversity of TexasHoustonUSA
  3. 3.Universities Space Research AssociationHoustonUSA
  4. 4.Pharmacotherapeutics Laboratory, SK/Human Adaptation and Countermeasures DivisionNASA Johnson Space CenterHoustonUSA

Personalised recommendations